Sawyer & Company Inc Purchases 15,229 Shares of Amgen Inc. $AMGN

Sawyer & Company Inc purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 15,229 shares of the medical research company’s stock, valued at approximately $6,419,000. Amgen makes up approximately 2.2% of Sawyer & Company Inc’s portfolio, making the stock its 12th biggest position.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Wellington Altus USA Inc. boosted its holdings in Amgen by 72.3% during the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after acquiring an additional 34 shares during the last quarter. Tower View Wealth Management LLC raised its holdings in shares of Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 63 shares during the last quarter. Nvwm LLC raised its holdings in shares of Amgen by 412.5% in the third quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 66 shares during the last quarter. Security National Bank of Sioux City Iowa IA bought a new position in shares of Amgen during the second quarter valued at about $36,000. Finally, Evergreen Advisors LLC bought a new position in shares of Amgen during the first quarter valued at about $37,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive Phase 3 Tezspire results: Amgen and AstraZeneca reported that Tezspire delivered statistically significant and clinically meaningful improvements in eosinophilic esophagitis. Results included sustained symptom improvement through 52 weeks and a 69% histologic remission rate, strengthening the drug’s potential as a growth driver if approved for this indication. Tezspire Phase 3 results
• Positive Sentiment: Analyst targets moved higher: Piper Sandler set a $457 price target, while Goldman Sachs raised its target to $481. The revisions indicate continued confidence in Amgen’s earnings outlook and pipeline, with the Goldman target implying additional upside from recent trading levels. Piper Sandler price target Goldman Sachs price target
• Positive Sentiment: Upcoming oncology presentation: Amgen will present data and host an investor webcast during the European Society for Medical Oncology Congress on October 24. New oncology data could provide further evidence that its pipeline and portfolio can support future growth. Amgen ESMO 2026 presentation
• Neutral Sentiment: Improving investment narrative: Recent coverage highlights Amgen’s earnings beat, expanding oncology and rare-disease portfolio, and strong cash generation. The company’s 2026 earnings guidance and dividend provide support, but investors still want evidence that newer products can deliver sustained growth. Amgen earnings investment story
• Negative Sentiment: Valuation and growth concerns remain: Commentary comparing Amgen with Bristol Myers Squibb notes that Amgen offers stronger top-line momentum but trades at a substantially higher valuation. With shares near their 52-week high, investors may require continued clinical and earnings execution to justify further gains. Amgen versus Bristol Myers Squibb

Amgen Stock Performance

Shares of NASDAQ:AMGN traded down $2.73 during mid-day trading on Wednesday, reaching $436.21. The company had a trading volume of 685,921 shares, compared to its average volume of 2,744,948. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The firm has a market cap of $235.83 billion, a price-to-earnings ratio of 27.11, a PEG ratio of 3.11 and a beta of 0.41. The company’s 50-day moving average price is $416.19 and its 200-day moving average price is $376.06. Amgen Inc. has a one year low of $288.00 and a one year high of $447.03.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The business had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same period in the prior year, the company earned $6.02 earnings per share. Amgen’s revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s dividend payout ratio is currently 62.65%.

Insiders Place Their Bets

In other news, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president owned 6,404 shares in the company, valued at $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 in the last ninety days. Insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Truist Financial boosted their price target on shares of Amgen from $362.00 to $380.00 and gave the stock a “hold” rating in a report on Wednesday, October 7th. Cantor Fitzgerald lifted their target price on shares of Amgen from $400.00 to $440.00 and gave the stock a “neutral” rating in a research report on Monday, October 5th. Sanford C. Bernstein boosted their price objective on Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. Bank of America upped their price objective on Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research note on Wednesday, August 5th. Finally, Barclays lifted their target price on Amgen from $380.00 to $400.00 and gave the stock an “equal weight” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $388.64.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.